Suraksha Diagnostics

About Suraksha Diagnostics

Established as a significant integrated healthcare player in Eastern India, Suraksha Diagnostics operates as a provider of pathology, molecular diagnostics, and diagnostic imaging services. The company was incorporated as a private limited entity on March 15, 2005, by Dr. Somnath Chatterjee and Ritu Mittal, and later converted to a public limited company in 2024. Dr. Chatterjee, the Chairman and Joint Managing Director, brings over 32 years of experience in the medical and diagnostics field, having earned his medical degree from the University of Calcutta in 1985. His role is central to the company's overall planning and business strategies.

Suraksha Diagnostics follows a hub-and-spoke operational model, which includes a central reference laboratory, satellite labs, diagnostic centers, and numerous sample collection points. This structure facilitates a comprehensive service offering, from routine pathology tests to advanced radiology procedures like MRI and CT scans, totaling over 2,300 types of tests. The business model is heavily focused on the business-to-consumer (B2C) segment, which accounts for the vast majority of its revenue, primarily serving individual patients through walk-ins and home collection services. The company also provides medical consultations through polyclinics integrated within its diagnostic centers. Revenue is generated directly from these testing and consultation services, targeting the expansive and fast-growing diagnostics market in Eastern and North-Eastern India.

The company's journey began with its first center in West Bengal in 2007, expanding to five operating centers by 2010. A significant milestone was achieved in 2013 with its first round of private equity funding from Lighthouse Funds. By 2016, it had secured a second round of funding led by Orbimed, which also marked the exit of the initial investor. This financial backing has supported its growth, including acquisitions and expansion into new territories like Meghalaya through a public-private partnership in 2019. More recently, in July 2025, the company invested ₹22 crore to launch a large-scale genomics lab, with plans for further significant investment to create one of Asia's most advanced genomics facilities. This new lab enhances its service portfolio with advanced genetic testing, including prenatal screening and hereditary cancer testing, positioning Suraksha at the forefront of precision diagnostics in the region.